...
首页> 外文期刊>Cardiovascular and Interventional Radiology: A Journal of Imaging in Diagnosis and Treatment >Intra-hepatic Abscopal Effect Following Radioembolization of Hepatic Metastases
【24h】

Intra-hepatic Abscopal Effect Following Radioembolization of Hepatic Metastases

机译:肝转放凝块放射性栓塞后的肝内胚痛效应

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose To search for abscopal effects (AE) distant to the site of radiation after sequential Yittrium-90 (Y-90) radioembolization (RE) of liver malignancies. Methods and Materials In this retrospective analysis, all patients treated by RE between 2007 and 2018 (n = 907) were screened for the following setting/conditions: sequential RE of left and right liver lobe in two sessions, liver-specific MRI (MRI1) acquired max. 10 days before or after first RE (RE1), liver-specific MRI (MRI2) acquired with a minimum time interval of 20 days after MRI1, but before second RE (RE2). No systemic tumor therapies between MRI1 and MRI2. No patients with liver cirrhosis. Metastases > 5 mm in untreated liver lobes were compared in MRI1 and MRI2 and rated as follows: same size or larger in MRI2 = no abscopal effect (NAE); > 30% shrinkage without Y-90 contamination in SPECT/CT = abscopal effect (AE). Results Ninety six of 907 patients met aforementioned criteria. Median time-frame between RE1 and MRI2 was 34 (20-64) days. These 96 cases had 765 metastases which were evaluable (median 5(1-40) metastases per patient). Four patients could be identified with at least one shrinking metastasis of the untreated site: one patient with breast cancer (3 metastases: 0 NAE; 3 AE), one patient with prostate cancer (6 metastases: 3 NAE; 3 metastases > 30% shrinkage but possible Y-90 contamination) and two patients with shrinkage of one metastasis each but less than 30%. Conclusion Our retrospective study documents AE after RE of liver tumors in 1 out of 96 cases, 3 other cases remain unclear.
机译:目的探讨肝脏恶性肿瘤序贯性Yittrium-90(Y-90)放射栓塞(RE)后,远处放射部位的远隔效应(AE)。方法和材料在这项回顾性分析中,对2007年至2018年间接受RE治疗的所有患者(n=907)进行以下设置/条件的筛查:在两个疗程中对左、右肝叶进行连续RE,在第一次RE(RE1)前后最多10天获得肝脏特异性MRI(MRI1),在MRI1后至少20天获得肝脏特异性MRI(MRI2),但在第二个RE(RE2)之前。MRI1和MRI2之间没有系统性肿瘤治疗。没有肝硬化患者。在MRI1和MRI2中比较未经治疗的肝叶中>5mm的转移瘤,并将其分级如下:MRI2中相同大小或更大的转移瘤=无副作用(NAE);>SPECT/CT无Y-90污染的30%收缩率=背向效应(AE)。结果907例患者中96例符合上述标准。RE1和MRI2之间的中位时间框架为34(20-64)天。这96例患者中有765个转移灶可评估(平均每位患者有5个(1-40个)转移灶)。四名患者至少有一个未治疗部位的转移缩小:一名乳腺癌患者(3个转移:0 NAE;3 AE),一名前列腺癌患者(6个转移:3 NAE;3个转移>30%缩小,但可能存在Y-90污染),两名患者各有一个转移缩小,但小于30%。结论我们的回顾性研究记录了96例中1例肝肿瘤复发后的不良事件,另外3例尚不清楚。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号